Skip to content
10-Q

Quarterly Report

ELITE PHARMACEUTICALS INC /NV/ ELTP

0001493152-25-023477

← back to feed
Filed
Nov 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Nov 14, 2025 1.07B sh
Shares Diluted Q2 2026 · Sep 30, 2025 1.14B sh
Shares Diluted Q2 2026 · Sep 30, 2025 1.08B sh
Shares Diluted Q2 2026 · Sep 30, 2024 1.07B sh
Shares Diluted Q2 2026 · Sep 30, 2024 1.07B sh
Capex Q2 2026 · Sep 30, 2025 $321.54K
Capex Q2 2026 · Sep 30, 2024 $870.97K
Operating Cash Flow Q2 2026 · Sep 30, 2025 $19.88M
Operating Cash Flow Q2 2026 · Sep 30, 2024 $4.6M
Stockholders Equity Q2 2026 · Sep 30, 2025 $61.58M
Stockholders Equity Q2 2026 · Jun 30, 2025 $47.68M
Stockholders Equity Q2 2026 · Mar 31, 2025 $53.52M
Stockholders Equity Q2 2026 · Sep 30, 2024 $47.27M
Stockholders Equity Q2 2026 · Jun 30, 2024 $58.25M
Stockholders Equity Q2 2026 · Mar 31, 2024 $57.58M
Current Liabilities Q2 2026 · Sep 30, 2025 $10.67M
Current Liabilities Q2 2026 · Mar 31, 2025 $11.84M
Total Liabilities Q2 2026 · Sep 30, 2025 $55.66M
Total Liabilities Q2 2026 · Mar 31, 2025 $42.87M
Current Assets Q2 2026 · Sep 30, 2025 $85.79M
Current Assets Q2 2026 · Mar 31, 2025 $57.74M
Total Assets Q2 2026 · Sep 30, 2025 $117.25M
Total Assets Q2 2026 · Mar 31, 2025 $96.39M
Eps Diluted Q2 2026 · Sep 30, 2025 $0.01
Eps Diluted Q2 2026 · Sep 30, 2025 $0.01
Eps Diluted Q2 2026 · Sep 30, 2024 −$0.01
Eps Diluted Q2 2026 · Sep 30, 2024 −$0.01
Eps Basic Q2 2026 · Sep 30, 2025 $0.01
Eps Basic Q2 2026 · Sep 30, 2025 $0.01
Eps Basic Q2 2026 · Sep 30, 2024 −$0.01
Eps Basic Q2 2026 · Sep 30, 2024 −$0.01
Sga Expense Q2 2026 · Sep 30, 2025 $4.03M
Sga Expense Q2 2026 · Sep 30, 2025 $7.43M
Sga Expense Q2 2026 · Sep 30, 2024 $2.27M
Sga Expense Q2 2026 · Sep 30, 2024 $4.24M
Rd Expense Q2 2026 · Sep 30, 2025 $1.39M
Rd Expense Q2 2026 · Sep 30, 2025 $3.06M
Rd Expense Q2 2026 · Sep 30, 2024 $1.97M
Rd Expense Q2 2026 · Sep 30, 2024 $4.13M
Net Income Q2 2026 · Sep 30, 2025 $13.7M
Net Income Q2 2026 · Sep 30, 2025 $7.82M
Net Income Q2 2026 · Jun 30, 2025 −$5.88M
Net Income Q2 2026 · Sep 30, 2024 −$11.04M
Net Income Q2 2026 · Sep 30, 2024 −$10.42M
Net Income Q2 2026 · Jun 30, 2024 $615.77K
Operating Income Q2 2026 · Sep 30, 2025 $8.21M
Operating Income Q2 2026 · Sep 30, 2025 $29.91M
Operating Income Q2 2026 · Sep 30, 2024 $3.48M
Operating Income Q2 2026 · Sep 30, 2024 $7.35M
Gross Profit Q2 2026 · Sep 30, 2025 $14.07M
Gross Profit Q2 2026 · Sep 30, 2025 $41.3M
Gross Profit Q2 2026 · Sep 30, 2024 $8.2M
Gross Profit Q2 2026 · Sep 30, 2024 $16.67M
Cost Of Revenue Q2 2026 · Sep 30, 2025 $22.25M
Cost Of Revenue Q2 2026 · Sep 30, 2025 $35.23M
Cost Of Revenue Q2 2026 · Sep 30, 2024 $10.68M
Cost Of Revenue Q2 2026 · Sep 30, 2024 $21.01M
Revenue Q2 2026 · Sep 30, 2025 $36.32M
Revenue Q2 2026 · Sep 30, 2025 $76.53M
Revenue Q2 2026 · Sep 30, 2024 $18.88M
Revenue Q2 2026 · Sep 30, 2024 $37.68M